Onasemnogene abeparvovec (Zolgensma) — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical coverage criteria and authorization requirements for intravenous onasemnogene abeparvovec (Zolgensma) for treatment of patients with spinal muscular atrophy (SMA) under Blue Cross NC benefits, including network and documentation requirements.
Added applicable revenue codes 0891 and 0892 associated with the HCPCS code(s).
Changed SMN2 gene copy requirement from three or fewer copies to four or fewer copies.
Duration of approval defined as 30 days for a one-time, single-dose treatment per lifetime.
Coverage Criteria for Onasemnogene abeparvovec (Zolgensma)
Initial Therapy Criteria
Covered when ALL of the following are met
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
Per the FDA-approved label and policy limits, onasemnogene abeparvovec is not for repeat administration and is not indicated for use in advanced SMA. Advanced SMA examples include complete paralysis of the limbs or permanent ventilator dependence (see definition criteria for invasive ventilation/tracheostomy or ≥16 hours/day of respiratory assistance continuously for ≥14 days in the absence of an acute, reversible illness).
Treatment with onasemnogene abeparvovec is considered not medically necessary when the patient does not meet the policy’s required clinical criteria. Specifically, coverage is excluded for patients who have advanced SMA as defined by the policy, or who fail to meet the genetic, age, antibody-titer, or prior‑therapy requirements (for example, patients aged ≥2 years, without documented bi‑allelic SMN1 mutations, with an AAV9 antibody titer > 1:50, with more than 4 SMN2 copies, or with prior gene replacement therapy).
Coding and Testing Requirements
| J3399 | Onasemnogene abeparvovec-xioi, per the FDA label reference |
| 0891 | Special Processed Drugs - FDA Approved Cell Therapy (applicable revenue code) |
| 0892 | Special Processed Drugs - FDA Approved Gene Therapy (applicable revenue code) |
Provider Actions, Documentation, and Authorization
Prior Authorization Required
Prior authorization required — coverage limited to patients meeting specified clinical criteria and dosing within FDA-labeled parameters.
- Prior authorization is required for onasemnogene abeparvovec-xioi (Zolgensma®).
- Duration of approval: 30 days (one-time, single-dose treatment per lifetime).
- Requested dose must be within FDA-labeled dosing for the requested indication; maximum units = 1 (HCPCS J3399).
Concurrent Therapy Restriction
Concurrent therapy with risdiplam (Evrysdi™) or nusinersen (Spinraza®) is not allowed. Any existing authorizations for these therapies will be closed upon approval of onasemnogene abeparvovec-xioi.
- Do not initiate onasemnogene abeparvovec-xioi if the patient is receiving risdiplam or nusinersen; confirm discontinuation and closure of prior authorizations as applicable.
Required Documentation
Medical record documentation is required to support the request. Submit clear documentation of patient age, genetic testing results, SMN2 copy number, anti-AAV9 antibody titer, prior SMA therapies, clinical status, prescriber specialty, and proposed dosing.
- Patient age (must be < 2 years at time of infusion).
- Diagnosis of SMA with bi-allelic SMN1 mutation.
- Genetic testing documentation (see below).
- SMN2 copy number (must be ≤ 4).
- Documentation that the patient does not have advanced SMA (e.g., complete limb paralysis or permanent ventilator dependence as defined in policy).
- Anti-AAV9 antibody titer ≤ 1:50 with lab report.
- Prescriber credentials: board-certified neurologist or pediatric neurologist experienced in SMA and practicing in a research/academic setting.
- Evidence the patient has not received prior gene replacement therapy (e.g., prior onasemnogene abeparvovec-xioi).
- Requested dose and calculation showing FDA-labeled dosing (1.1 x 10^14 vg/kg) and total units (maximum units = 1).
Genetic Testing Documentation
Confirmation of diagnosis must include genetic testing showing bi-allelic SMN1 mutations.
- Acceptable genetic test results: homozygous deletion of SMN1 exon 7 OR compound heterozygosity for SMN1 exon 7 deletion plus a small (point) mutation.
- Provide formal genetic testing report documenting the specific SMN1 findings.
- Include SMN2 copy number testing results.
Triggers for Potential Denial
Triggers for potential denial — requests are at high risk of denial if required clinical or laboratory documentation is missing or if patient characteristics fall outside policy criteria.
- Patient is ≥ 2 years of age at time of infusion.
- No documentation of bi-allelic SMN1 mutation (missing or inconclusive genetic test report).
- SMN2 copy number documented as greater than 4.
- Evidence of advanced SMA (complete paralysis of limbs or permanent ventilator dependence as defined in policy).
- Anti-AAV9 antibody titer > 1:50 or no antibody testing provided.
- Concurrent treatment with risdiplam or nusinersen without documentation of discontinuation and authorization closure.
- Prescriber not a board-certified neurologist/pediatric neurologist experienced in SMA or not practicing in an appropriate research/academic setting.
- Prior receipt of onasemnogene abeparvovec-xioi or other gene replacement therapy for SMA.
Background
Onasemnogene abeparvovec (Zolgensma) is an intravenous, adeno-associated virus serotype 9 (AAV9)–based gene replacement therapy approved for the treatment of spinal muscular atrophy (SMA) in children younger than 2 years of age with bi‑allelic mutations in the SMN1 gene. It is intended as a single, one-time IV infusion at a weight‑based dose per the FDA label and the policy; it is expressly not for repeat administration and should not be used in patients meeting the policy definition of advanced SMA.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.